Clinical trials: Prostate Cancer With Intermediate Risk
Prostate Cancer
A Study of Shorter Course Hormone Therapy and Radiation for High-risk Prostate Cancer
The purpose of this study is to find out whether combining a shorter than standard course of ADT with standard prostate brachytherapy and hypofractionated external beam radiation therapy is a safe and effective way to prevent…
- Trial name
- NCT05100472
- Testing
- Androgen deprivation therapy (ADT), Brachytherapy, Hypofractionated pelvic External beam radiation
- Where
- 7 sites in United States
- Volunteers
- 50 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Intermediate Risk Prostate Cancer
Enzalutamide + External Beam Rt For Prostate
This research study is evaluating a drug called enzalutamide in combination with external beam radiation therapy as a possible treatment for prostate cancer.
- Trial name
- NCT02028988
- Testing
- Enzalutamide, External Beam Radiation
- Where
- 3 sites in United States
- Volunteers
- 64 people
- Sponsor
- Dana-Farber Cancer Institute
Prostate Cancer
Study of Focal Ablation of the Prostate With NanoTherm® Therapy System for Intermediate-Risk Prostate Cancer
Stage 2B: NanoTherm ablation of focal prostate cancer in small lesions in Gleason 3+4 disease. The outcome of this ablation is validated by a transperineal biopsy at 4 months after ablation.
- Trial name
- NCT05010759
- Testing
- NanoTherm Ablation
- Where
- 4 sites in United States
- Volunteers
- 3 people
- Sponsor
- MagForce USA
Prostate Cancer
Single-Dose Image-Guided Radiotherapy With Urethral Sparing and DIL Boost for Intermediate-Risk Prostate Cancer (PROSINT II)
This prospective single-arm phase II study evaluates the safety, feasibility, quality-of-life effects, PSA kinetics, imaging response, and clinical outcomes of definitive ultra-high dose single-fraction external beam radiation…
- Trial name
- PROSINT II (NCT04035642)
- Testing
- IGRT-VMAT / SDRT 24 Gy in 1 fraction, Rectal balloon with air filling, Urethral catheter loaded with beacon transponders
- Where
- Portugal
- Volunteers
- 200 people
- Sponsor
- Fundacao Champalimaud
Prostate Adenocarcinoma, Stage I Prostate Cancer
Stereotactic Body Radiation Therapy in Treating Patients With Low- and Intermediate-Risk Prostate Cancer
This clinical trial studies stereotactic body radiation therapy in treating patients with low- and intermediate-risk prostate cancer.
- Trial name
- NCT01737151
- Testing
- stereotactic body radiation therapy, four fraction split-course SBRT
- Where
- 3 sites in United States
- Volunteers
- 19 people
- Sponsor
- Virginia Commonwealth University
Prostate Cancer, Prostate Adenocarcinoma
Hypofractionated Accelerated Pelvic Nodal Radiotherapy (GCC 2048)
A phase I trial to determine the safety of delivering three sequentially shorter RT schedules (20, 16, and 12 fractions) of HypoFx pelvic nodal RT in combination with a HypoFx, simultaneous integrated boost (SIB) to the prostate…
- Trial name
- NCT04486755
- Testing
- Hypofractionated Radiation Therapy
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Maryland, Baltimore
Prostate Adenocarcinoma
Mild Hypofractionation With Proton Therapy or IMRT for Intermediate-Risk Prostate Cancer
This is a study to first establish feasibility of the study and then to register the treatment data of adult patients with a diagnosis of intermediate risk of prostate cancer presenting for definitive radiation treatment with…
- Trial name
- NCT01352429
- Testing
- Proton Therapy, IMRT
- Where
- 2 sites in United States
- Volunteers
- 303 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Prostate Cancer
Androgen Suppression With Stereotactic Body or External Beam Radiation Therapy (ASSERT)
Two radiation therapy techniques are commonly used for the treatment of intermediate and high risk prostate cancer: brachytherapy and external beam radiation therapy (EBRT). However, both have limitations.
- Trial name
- ASSERT (NCT02594072)
- Testing
- stereotactic ablative radiotherapy, external beam radiation therapy, Zoladex ®
- Where
- 2 sites in Canada
- Volunteers
- 80 people
- Sponsor
- University of British Columbia
Prostatic Cancer
High-dose Brachytherapy Boost With Stereostatic Body Radiation Therapy to Intermediate or Higher Risk Prostate Cancer
The objective of this phase I/II trial is to prospectively evaluate the toxicity and therapeutic efficacy of Stereostatic Body Radiation Therapy (SBRT) to prostate and pelvic lymph nodes in combination with high-dose-rate (HDR)…
- Trial name
- NCT05754580
- Testing
- High Dose Brachytherapy, Stereostatic Body Radiation Therapy
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- University of Nebraska
Prostate Cancer Patients Treated by Radiotherapy, Prostate Cancer (Adenocarcinoma)
A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec
Phase 2a, open-label, multi-center study evaluating biomarkers and biodistribution of aglatimagene besadenovec plus valacyclovir in men with localized, intermediate-risk prostate cancer who are planning to receive external beam…
- Trial name
- NCT07332000
- Testing
- aglatimagene besadenovec + valacyclovir, External Beam Radiation Therapy (EBRT)
- Where
- 7 sites in United States
- Volunteers
- 45 people
- Sponsor
- Candel Therapeutics, Inc.
Diabetes, Prostate Cancer
Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility Study
The goal of this clinical research study is to determine how well a tirzepatide-assisted weight loss program works before a prostatectomy in patients with intermediate risk prostate cancer
- Trial name
- NCT06759701
- Testing
- Tirzepatide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
Prospective Evaluation of Mp-MRI, MR-guided Biopsy, and Molecular Markers for Active Surveillance of Prostate Cancer
Active Surveillance (AS) is a treatment option in patients with favorable risk prostate cancer. According to the current guidelines patients are monitored by prostate specific antigen (PSA) testing (every 3 months) and regular…
- Trial name
- PROMM-AS (NCT03979573)
- Testing
- Multiparametric MRI, Radiomics, MR-guided Biopsy
- Where
- Germany
- Volunteers
- 90 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Prostate Adenocarcinoma
Perioperative Atezolizumab With MVA-BN-Brachyury and PROSTVAC For Intermediate-Risk And High-Risk Localized Prostate Cancer
This study is a prospective, open label, single arm phase II trial. A total of 22 patients will be treated with atezolizumab, PROSTVAC, and pre-operative MVA-BN-Brachyury to confirm the efficacy of prostatic combination…
- Trial name
- AtezoVax (NCT04020094)
- Testing
- MVA-BN-Brachyury
- Where
- United States
- Sponsor
- University of Utah
Prostate Cancer With Intermediate Risk
Feasibility Study of a Dose Increase by a Boost of Curietherapy in Pulse Dose Rate (PDR) Associated With the Extern Radiotherapy in Prostate Cancer
The objective of the trial is to evaluating the feasibility of dose increase by a boost of curietherapy in PDR (at least 40 Gy on D95) associated to extern radiotherapy (34 Gy) in intermediate risk in prostate cancer.
- Trial name
- CURIEBOOST (NCT01039038)
- Testing
- curietherapy and radiotherapy
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Centre Francois Baclesse
Prostate Cancer Patients Undergoing External Radiation and Seed Implantation, High Risk Localised Prostate Carcinoma
Addition of Focal Boost to Primary Radiotherapy for Prostate Cancer in 12 or 20 Fractions
Every year, about 700 Danish men get radiotherapy for prostate cancer with a high-risk of later progression. The risk of relapse is about 40 % after 5 - 8 years, so we need better treatment for these patients in Denmark and…
- Conditions
- Prostate Cancer Patients Undergoing External Radiation and Seed Implantation, High Risk Localised Prostate Carcinoma, Locally Advanced Prostate Cancer, Unfavourable Intermediate Risk Prostate Cancer
- Trial name
- DAPROCA10 (NCT07343349)
- Testing
- Addition of focal boost and hypofractionation
- Where
- 3 sites in Denmark
- Volunteers
- 1,016 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Prostate Cancer
A Prospective, Single-Arm, Pilot Study of the ALPFA BPH PFA System in Men With Low, Intermediate and High-Risk Prostate Cancer
The primary objective of this study is to evaluate the safety and effectiveness of PFA in patients with localized prostate cancer.
- Trial name
- NCT07492381
- Testing
- ALPFA BPH PFA System
- Volunteers
- 50 people
- Sponsor
- ALPFA Medical
Low or Intermediate Risk Prostate Cancer
Advanced Imaging for Radiotherapy Treatment Planning and Guidance for Low-Intermediate Risk Prostate Cancer (Margin)
The integration of magnetic resonance imaging (MRI) in the treatment planning process for prostate cancer will reduce uncertainties in delineation of the prostate gland, and will enable delineation of the urethra, penile bulb…
- Trial name
- NCT00890006
- Testing
- Advanced imaging for radiotherapy planning and guidance
- Where
- Canada
- Volunteers
- 99 people
- Sponsor
- University Health Network, Toronto
Prostate Cancer
Proton Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
- Trial name
- NCT01045226
- Testing
- Proton Beam Radiation Therapy, Quality-of-Life assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Prostate Cancer
Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells and shrink tumors. Androgens can cause the growth of prostate cancer cells.
- Trial name
- NCT00936390
- Testing
- bicalutamide, flutamide, LHRH agonist (antagonist) therapy
- Where
- 518 sites in United States, Canada
- Volunteers
- 1,538 people
- Sponsor
- Radiation Therapy Oncology Group
Prostatic Adenocarcinoma
Hypofractionated Radiotherapy Versus Stereotactic Irradiation With Hyaluronic Acid
The present randomized, open, multicentric Phase II trial, in parallel groups with two arms of treatment, compares the treatment A, moderate hypofractionated radiotherapy of 62Gy, to treatment B, stereotactic irradiation of 37.5…
- Trial name
- RPAH2 (NCT02361515)
- Testing
- Moderate hypofractionated radiotherapy, Stereotactic radiotherapy
- Where
- 7 sites in France
- Volunteers
- 96 people
- Sponsor
- Hospices Civils de Lyon